Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Live From Denver: TCT 2017, Day Three

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

November 01, 2017

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Presentation TCT 2017

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Presenter: Kurt Huber, Jamil Abdalla Saad, Dimitrios Alexopoulos, Antonio L. Bartorelli, Bjorn Redfors, Carlos E. Uribe

October 31, 2017

Long-term Evidence Supports Better Survival for Women Than Men After TAVR

News Daily News

Long-term Evidence Supports Better Survival for Women Than Men After TAVR

October 23, 2017

PLATINUM DIVERSITY - Outcomes With Coronary Stenting in Women and Minorities

Podcast TCTMD Talking Points

PLATINUM DIVERSITY - Outcomes With Coronary Stenting in Women and Minorities

October 04, 2017

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

News Daily News

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

August 10, 2017

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

News Features

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

Yael L. Maxwell

August 02, 2017

Newly Proposed Classification of AS Focuses on Baseline Cardiac Damage as Outcome Predictor

News Daily News

Newly Proposed Classification of AS Focuses on Baseline Cardiac Damage as Outcome Predictor

July 26, 2017

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

June 02, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.